Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC [22P]
(2021) European Lung Cancer Virtual Congress (ELCC 2021) — Location: Virtual (25.March.2021)
Files
2021_Riudavets_J_Thorac_Oncol.pdf
Open Access - Adobe PDF
- 88.55 KB
Details
- Authors
- Abstract
- BACKGROUND: EGFR mutations (EGFRm) represent 10–15% of advanced non-small cell lung cancer (NSCLC) in European patients (pts). Tissue molecular profiling is the gold-standard, but liquid biopsy (LB) offers a non-invasive alternative. Digital droplet PCR (ddPCR) is a fast, highsensitive and low-cost LB to detect specific molecular alterations. We aimed to describe ddPCR clinical utility for EGFRm detection in advanced NSCLC. METHODS: Prospective blood sample collection in advanced NSCLC pts harboring EGFRm either at baseline and/or at progression (PD) between Jan/16 and Sep/20 at Gustave Roussy. LB was performed by ddPCR (Stilla®): sensitizing (exon19 deletion; exon21 [L858R]) and T790M resistance EGFRm. We defined high tumor burden as >2 metastatic sites. We analyzed EGFRm detection by ddPCR at these timepoints. [...]
- Affiliations
Citations
Riudavets, M., Lamberts, V., Auclin, E., Aldea, M., Vasseur, D., Jovelet, C., Naltet, C., Lavaud, P., Gazzah, A., Aboubakar Nana, F., Remon, J., Rouleau, E., Lacroix, L., Ngocamus, M., Nicotra, C., Besse, B., Planchard, D., & Mezquita, L. (2021). Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC [22P]. Journal of Thoracic Oncology, 16(4), S707-S708. https://doi.org/10.1016/s1556-0864(21)01864-5 (Original work published 2021)